Points to Consider for Microbial Control in ATMP Manufacturing
Points to Consider for Microbial Control in ATMP Manufacturing Team

Authors

**Friedrich von Wintzingerode**, PhD, Roche-Genentech (Co-chair)
**Marc Glogovsky**, ValSource, Inc. (Co-chair)
**Daniel Bice**, Adaptimmune Therapeutics, PLC
**Lori Dingedine**, Spark Therapeutics, Inc.
**Phil Duncanson**, PhD, AstraZeneca

**Irving Ford**, Adaptimmune Therapeutics, PLC
**David Roesti**, PhD, Novartis
**Thomas Schomogy**, Pfizer Inc.
**Christine Sherman**, Takeda
**Marsha Steed**, Resilience
# Table of Contents

## INTRODUCTION

- Scope ........................................................................ 1

## GENERAL CONSIDERATIONS

- Control through Facility Design ........................................ 2
- Control through Equipment and Instrumentation Design and Maintenance ........................................ 2
- Control through Analyst and Operator Gowning and Qualification ........................................ 2
- Control Confirmed by Microbiological Process Monitoring ........................................ 2

## TOPIC 1: INCOMING APERESIS/LEUKAPERESIS MATERIAL

- Q1-1: What are the risks of contamination during apheresis/leukapheresis collection? ................ 3
- Q1-2: Is the microbial contamination risk different for autologous than for allogeneic processes? ........ 4
- Q1-3: When and where should microbiological testing of apheresis/leukapheresis be performed? ........ 5
- Q1-4: What are the key points of consideration when defining the apheresis/leukapheresis microbial test plan? ........................................................ 6

## TOPIC 2: ATMP STABILITY STUDIES

- Q2-1: What microbiological methods are recommended for ATMP stability studies? ........ 7

## TOPIC 3: MATERIALS USED TO MANUFACTURE ATMPs

- Q3-1: Are there specific microbiological considerations for materials used to manufacture ATMPs? ...... 8

## TOPIC 4: GENERAL REQUIREMENTS FOR MICROBIOLOGICAL SAMPLES FOR ATMP TESTING

- Q4-1: What are the general requirements for ATMP product testing samples, reserve samples and retain samples, and validation samples? ........ 9

## TOPIC 5: ASEPTIC PROCESSING SIMULATIONS

- Q5-1: Are there any specific requirements for aseptic process simulation (also known as media fill) for ATMPs? ........................................................ 10

## TOPIC 6: BIOBURDEN AND STERILITY TESTING

- Q6-1: Why are the traditional bioburden and sterility test volumes a challenge for ATMPs? ........ 11
- Q6-2: Is there regulatory support for reduced microbiological test volumes? .............................. 12
- Q6-3: Are method suitability studies (qualification/bacteriostasis & fungistasis) required for ATMPs? ........................................................ 13
- Q6-4: How can product volume be preserved when performing suitability studies? ..................... 14

## TOPIC 6.1: BIOBURDEN TESTING

- Q6.1-1: What test methods should be used for ATMP bioburden testing? ........................................ 15
- Q6.1-2: What volumes are required for bioburden test samples? .................................................. 16
- Q6.1-3: What is an example test plan for ATMPs regarding bioburden sampling? ......................... 17
- Q6.1-4: Do ATMPs require specific considerations regarding bioburden quality control sample hold time? ................................................ 18

## TOPIC 6.2: STERILITY TESTING

- Q6.2-1: What test methods should be used for ATMP sterility testing? ........................................ 19
- Q6.2-2: What is the appropriate sampling point for sterility release testing if drug product is stored frozen? ................................................ 20
- Q6.2-3: Is sterility testing required for plasmids? .... 21
- Q6.2-4: What is an example test plan for ATMPs regarding sterility sampling? .......................... 22

## TOPIC 6.3: RAPID STERILITY TEST METHODS

- Q6.3-1: Which aspects should be considered when selecting a rapid sterility test method for ATMPs? ................................................ 23

## TOPIC 7: ENDOTOXIN TESTING

- Q7-1: Final product of most ATMPs represents a complex sample matrix. Which aspects must be considered for an appropriate endotoxin test? ... 24
- Q7-2: Cell therapy products are manufactured in closed process equipment under aseptic conditions. Is endotoxin in-process testing needed for these products? .................. 26
- Q7-3: Is control of endotoxin via the incoming materials sufficient not to have to perform endotoxin in-process product testing for ATMPs? ........................................ 27

## TOPIC 8: MYCOPLASMA TESTING

- ......................................................... 28
Q8-1: Is mycoplasma testing a mandatory requirement for ATMPs or can firms perform testing following a risk-based approach? ...... 28
Q8-2: What is the appropriate process step/sampling for testing mycoplasma? .......................... 29
Q8-3: What are appropriate reference organisms for validation of mycoplasma testing? .............. 30

TOPIC 9: ADVENTITIOUS VIRUS SAFETY ............... 31
Q9-1: Do ATMPs require adventitious virus safety strategies different from those for traditional biologics manufacturing? .......................... 31

REFERENCES .......................................................... 32

FIGURES AND TABLES INDEX

Table 6.1-3-1 Example Test Plan for ATMP Process and Product Bioburden Testing .......... 17